

1 **Supplementary Data**


2 **Clinical trial design and primary clinical outcomes**

3 We conducted a single-arm, open-label Phase II clinical trial: the DARANA study (Dynamics of Androgen
4 Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation; NCT03297385). In this
5 study, 56 men with primary high-risk (Gleason score ≥ 7) PCa were enrolled. Mean age at inclusion was
6 67 years, baseline serum PSA 12.8 ng/mL and the majority of patients had an ISUP2 (28%) or ISUP4 (36%)
7 PCa (**Fig. 1A; Table 1**). Prior to ENZ therapy, magnetic resonance imaging (MRI)-guided core needle tumor
8 biopsies were taken. Subsequently, patients received neoadjuvant ENZ treatment (160 mg/day) for three
9 months without androgen deprivation therapy. 55 patients completed therapy without dose adjustments,
10 while one patient (DAR37) discontinued ENZ three weeks prematurely. All patients underwent a robotic-
11 assisted laparoscopic prostatectomy (RALP). Based on baseline MRI information and palpation, additional
12 tumor-targeted core needle biopsies were taken *ex vivo*. 30% of prostatectomy specimens had positive
13 surgical margins, which was comparable to 1492 non-treated historical controls with Gleason ≥ 7 (34%; see
14 methods) and analogous to a previous neoadjuvant study on ENZ alone versus ENZ in combination with
15 the 5α -reductase inhibitor dutasteride and androgen deprivation therapy in high-risk patients for 6 months,
16 describing 26.1% positive margins in the triple-therapy arm (1). No differences in pre and post treatment T-
17 stages were observed. A higher incidence of ypN1 lymph nodes than cN1 lymph nodes was possibly due
18 to differences in accuracy of radiographic pre-treatment assessments versus post-treatment histological
19 assessments. After a mean follow-up of 37 months, the mean time to biochemical recurrence was 12
20 months (**Supplementary Fig. S1A; Supplementary Table S1**).


21 **Supplementary Figures**

Supplementary Figure S1

A Biochemical recurrence-free survival:



B The DARANA study: sample flow diagram




22

23 **Figure S1: The DARANA study.**

- 24 (A) Kaplan-Meier curve showing the biochemical recurrence (BCR)-free survival of the DARANA cohort, treated with 3
25 months of neoadjuvant ENZ prior to prostatectomy. BCR was defined as a rise in Prostate-specific antigen (PSA)
26 serum levels of ≥ 0.2 ng/mL.
- 27 (B) Sample flow diagram indicating the quality control measures applied to each sample, and the number of samples
28 passing the respective cut-offs per omics data stream.
- 29

Supplementary Figure S2



30


31 **Figure S2: Tissue ChIP-seq quality metrics.**

32 (A) Boxplots showing the median total number of reads for AR (red), FOXA1 (blue) and H3K27ac (green) ChIP-seq, as
 33 well as ChIP-seq input (gray) samples.

34 (B) Boxplots indicating the percentage of aligned reads per ChIP factor.

- 35 (C) Scatter plot of phantom peak results, showing the normalized strand cross-correlation coefficient (NSC) and relative
36 strand cross-correlation coefficient (RSC) scores for each ChIP-seq and input sample.
- 37 (D) Boxplot showing the number of peaks per ChIP-seq sample. Peak calling was performed over matched input control
38 samples.
- 39 (E) Boxplots indicating the fraction of reads in peaks (FRiP) score per sample.
- 40

Supplementary Figure S3




41

42 **Figure S3: Correlation between tissue ChIP-seq samples.**

43 Boxplots indicating the Pearson correlation of ChIP-seq samples based on peak occupancy. Both, pairwise
44 comparisons within the same ChIP-seq dataset (AR vs. AR, FOXA1 vs. FOXA1, H3K27ac vs. H3K27ac), and between
45 different datasets (AR vs. FOXA1, AR vs. H3K27ac, FOXA1 vs. H3K27ac) are shown. The corresponding correlation
46 matrix is shown in **Fig. 2B**.

47

Supplementary Figure S4



48

49 **Figure S4: Differential FOXA1 chromatin binding upon ENZ treatment.**

50 (A) Principle component analysis (PCA) plot based on peak occupancy of AR ChIP-seq data. Color indicates the treatment
 51 status of pre- (light red) and post- (dark red) ENZ AR samples.

52 (B) Representative tornado plots visualizing FOXA1 ChIP-seq signal (in fragments per kilobase per million reads mapped
 53 (FPKM)) at pre-enriched and post-enriched FOXA1 binding sites before (pre) and after (post) ENZ treatment in one
 54 patient. Data are centered at FOXA1 peaks depicting a 5-kb window around the peak center.


55 (C) Quantification of the average signal intensity at pre-enriched (top) and post-enriched (bottom) FOXA1 binding sites
 56 before (light blue) and after (dark blue) ENZ treatment shown in (B). Data are centered at FOXA1 peaks depicting a
 57 2.5-kb window around the peak center.

58 (D) Pie charts showing the genomic distribution of pre-enriched (top) and post-enriched (bottom) FOXA1 binding sites.

59 (E) Word clouds show motif enrichment at pre-enriched (left) and post-enriched (right) FOXA1 sites. The font size
 60 represents the z-score and colors correspond to transcription factor families.

61

Supplementary Figure S5



62

63 **Figure S5: Copy number variation at differential FOXA1 sites.**

64

(A) Boxplot showing the median copy number ratio at pre-enriched (left) and post-enriched (right) FOXA1 binding sites

65

over all pre-treatment and post-treatment samples.

66 (B-C) Heatmap depicting segmented CNV data at pre-enriched (B) and post-enriched (C) FOXA1 binding sites in pre-
67 and post-treatment samples (columns). Differential FOXA1 sites are ordered per chromosome (rows) and heatmap
68 color indicates copy number gains and losses (z-score).


69 (D) Scatter plot showing the correlation between FOXA1 ChIP-seq data and CNV-seq data for paired pre-treatment and
70 post-treatment samples (n=15). Plotted is the normalized ChIP readcount difference (post vs. pre ENZ) against the
71 CNV ratio difference (post vs. pre ENZ) at all differential FOXA1 binding sites (n=1,905) per patient. CNV cut-offs of \pm
72 0.1 (dotted vertical lines) and mean Pearson correlation ($R = 0.11$; range: -0.02 – 0.26) are indicated. Differential
73 FOXA1 binding sites (dots) are colored based on their enrichment (pre-enriched vs. post-enriched) and recurrent CNV
74 events found in ≥ 3 patients are highlighted.

75 (E) Stacked bar plot indicating the fraction of differential FOXA1 sites that show recurrent CNVs shown in (D) with CNV
76 ratio > 0.1 for post-enriched and < 0.1 for pre-enriched FOXA1 sites in 3 or more patients (pre: n=24/475, post:
77 n=20/1,430).


78

Supplementary Figure S6


A Occupancy of differential FOXA1 sites in all DARANA samples:






B FOXA1 expression pre vs. post ENZ:




C H3K27ac ChIP-seq signal at pre-treatment FOXA1 sites:




E Correlation of AR and H3K27ac ChIP-seq signals at differential and consensus FOXA1 binding sites in untreated tumors (n=87):



D H3K27ac ChIP-seq signal at post-treatment FOXA1 sites:



F Overlap between diff. FOXA1 sites and metARBS:



80 **Figure S6: Characterization of differential FOXA1 sites.**


- 81 (A) Coverage heatmap showing occupancy of differential (pre-/post-enriched) and consensus FOXA1 peaks in all
82 generated pre- and post-treatment ChIP-seq samples. Heatmap color indicates region read counts (z-score) at pre-
83 enriched, post-enriched and consensus FOXA1 sites (rows) in the pre- and post-treatment AR (red), FOXA1 (blue)
84 and H3K27ac (green) ChIP-seq data streams (columns).
- 85 (B) Boxplot showing normalized FOXA1 gene expression before and after 3 months of neoadjuvant ENZ treatment. ****,
86 $P < 0.0001$ (Mann-Whitney U-test).
- 87 (C-D) Representative tornado plots (top) and average density plots (bottom) visualizing H3K27ac ChIP-seq signal (in
88 FPKM) at pre-enriched (C) and post-enriched (D) FOXA1 binding sites in 3 patients (DAR24, DAR39, DAR52) before
89 and after ENZ treatment. Data are centered at FOXA1 peaks depicting a 10-kb (heatmaps) or 2.5-kb (density plots)
90 window around the peak center.
- 91 (E) Scatter plots showing the correlation between AR and H3K27ac ChIP-seq signals at pre-enriched (top), post-enriched
92 (middle) and consensus (bottom) FOXA1 sites in treatment-naïve primary prostate tumors (n=87). Pearson correlations
93 for pre-enriched ($R = 0.54$), post-enriched ($R = 0.78$) and consensus ($R = 0.50$) FOXA1 sites are indicated.
- 94 (F) Bar chart indicating the overlap between pre-enriched (left) and post-enriched (right) FOXA1 binding sites, and
95 previously identified (2) metastasis-specific AR binding sites (metARBS). ****, $P < 0.0001$ (Fisher's exact test).

96

Supplementary Figure S7


A

Top downregulated pathways upon ENZ treatment:



B

Top upregulated pathways upon ENZ treatment:



97

98 **Figure S7: Differential gene expression.**

99

100

101


102

Heatmaps depicting differential gene expression of top downregulated (A) and top upregulated (B) pathways upon ENZ treatment. Unsupervised hierarchical clustering of pre- and post-treatment RNA-seq samples is based on the expression of genes that define the respective hallmark gene sets. Color scale indicates gene expression (z-score).

Supplementary Figure S8


A

Cluster assignment of pre-treatment samples:



B

Cluster assignment of pre- and post-treatment samples:



103

104 **Figure S8: Molecular subtyping.**

105

106


107

108

109

Unsupervised hierarchical clustering of pre-treatment (A) or pre- and post-treatment (B) RNA-seq samples using 285 genes differentially expressed across 3 previously reported PCa subtypes (3). For each sample, the assigned cluster affiliation as well as the ERG gene expression levels are indicated below the branching. The genes (rows) are ordered per cluster and the color scale of the heatmap indicates gene expression (z-score).

Supplementary Figure S9



110

111 **Figure S9: Cistromic and transcriptomic profiling of circadian rhythm core components.**


112 (A) Representative example snapshots of H3K27ac ChIP-seq signal at the *ARNTL* gene locus before (top) and after
 113 (bottom) ENZ treatment. Shown are matched pre- and post-treatment ChIP-seq data of 3 patients (DAR04, DAR05,
 114 DAR06).

115 (B) Boxplot showing normalized CLOCK gene expression before and after 3 months of neoadjuvant ENZ treatment. ns, P
 116 > 0.05 (Mann-Whitney U-test).

117 (C) Boxplots depicting normalized CLOCK gene expression in ENZ non-responders (BCR ≤ 6 months; $n=8$) and
 118 responders (no BCR; $n=29$) in the pre- (left) and post-treatment (right) setting separately. ns, $P > 0.05$ (Mann-Whitney
 119 U-test).

120

Supplementary Figure S10



121

122

Figure S10: Characterizing the FOXA1 cistrome in hormone-naïve and ENZ-resistant PCa cell lines.

123


(A) Boxplot showing the number of FOXA1 peaks per ChIP-seq condition (Pre^{LNCaP}, Post^{LNCaP}, Res^{LNCaP-42D}). Peak calling

124

was performed over matched cell line input control samples.

- 125 (B) Venn diagram indicating the overlap of FOXA1 binding sites in all tested cell line conditions (Pre^{LNCaP}, Post^{LNCaP},
126 Res^{LNCaP-42D}). For each condition, only peaks present in both replicates were included. The FOXA1 consensus cistrome
127 across conditions (n=35,602 sites) was used for genomic distribution (C) and motif enrichment (D) analyses.
- 128 (C) Pie chart showing the genomic distribution of consensus FOXA1 binding sites.
- 129 (D) Word cloud shows motif enrichment at consensus FOXA1 sites. The font size represents the z-score and colors
130 correspond to transcription factor families.
- 131 (E) Representative example snapshots of FOXA1 ChIP-seq signal at two pre-enriched (left) and two post-enriched (right)
132 FOXA1 binding sites. Per genomic location, the pre- and post-treatment FOXA1 ChIP-seq signal from one patient
133 (top), as well as the signal in all tested cell line models (bottom) is shown. For cell lines, the average of two biological
134 replicates is represented. Y-axis indicates ChIP-seq signal in FPKM.
- 135 (F) Correlation heatmap based on FOXA1 peak occupancy. Clustering of the samples is based on all called peaks and
136 represents Pearson correlations between individual ChIP-seq samples. The column color bars indicate the ChIP-seq
137 condition (Pre^{LNCaP}, Post^{LNCaP}, Res^{LNCaP-42D}) and replicate information (Rep1, 2).
- 138 (G) Principal component analysis (PCA) plot based on FOXA1 peak occupancy. Each dot represents a ChIP-seq sample
139 that is colored per condition (2 replicates per condition).
- 140

Supplementary Figure S11



141

142

Figure S11: Characterizing the ARNTL cistrome in hormone-naïve and ENZ-resistant PCa cell lines.

- 143 (A) Boxplot showing the number of ARNTL peaks per ChIP-seq condition (Pre^{LNCaP}, Post^{LNCaP}, Res^{LNCaP-42D}). Peak calling
144 was performed over matched cell line input control samples.
- 145 (B) Representative example snapshots of ARNTL ChIP-seq signal at canonical circadian rhythm genes. The average of
146 two biological replicates is represented. Y-axis indicates ChIP-seq signal in FPKM.
- 147 (C) Pie chart showing the genomic distribution of ARNTL consensus sites (shared across all conditions; n=1,515 sites).
148 The corresponding Venn diagram is shown in **Fig. 6E**.
- 149 (D) Word cloud shows motif enrichment at ARNTL consensus sites (n=1,515). The font size represents the z-score and
150 colors correspond to transcription factor families. Since the human ARNTL motif is not part of the tested database, the
151 homologous mouse motif (Arntl) was included.
- 152 (E) Representative example snapshots of ARNTL ChIP-seq signal at two post-enriched FOXA1 binding sites. Per genomic
153 location, the pre- and post-treatment FOXA1 ChIP-seq signal from one patient, as well as the ARNTL signal in all
154 tested cell line models (bottom) is shown. For cell lines, the average of two biological replicates is represented. Y-axis
155 indicates ChIP-seq signal in FPKM.
- 156 (F) Correlation heatmap based on ARNTL peak occupancy. Clustering of the samples is based on all called peaks and
157 represents Pearson correlations between individual ChIP-seq samples. The column color bars indicate the ChIP-seq
158 condition (Pre^{LNCaP}, Post^{LNCaP}, Res^{LNCaP-42D}) and replicate information (Rep1, 2).
- 159 (G) Principal component analysis (PCA) plot based on ARNTL peak occupancy. Each dot represents a ChIP-seq sample
160 that is colored per condition (2 replicates each).
- 161

162 **Supplementary References**

163

164 1. Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bublely GJ, *et al.*
165 Neoadjuvant Enzalutamide Prior to Prostatectomy. *Clin Cancer Res* **2017**;23(9):2169-76 doi
166 10.1158/1078-0432.CCR-16-1357.

167 2. Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, *et al.* Prostate cancer reactivates
168 developmental epigenomic programs during metastatic progression. *Nat Genet* **2020**;52(8):790-9
169 doi 10.1038/s41588-020-0664-8.

170 3. Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, *et al.* Integrative
171 epigenetic taxonomy of primary prostate cancer. *Nat Commun* **2018**;9(1):4900 doi
172 10.1038/s41467-018-07270-2.

173